GSK Shingrix Prefilled Syringe Approved in Japan

London, United Kingdom, September 10, 2026

Japan Approves New Shingrix Presentation

The MHLW approval covers the prefilled syringe presentation of Shingrix, a non-live recombinant vaccine used to help prevent herpes zoster and associated complications. The new presentation is designed to simplify vaccine preparation and administration by providing the vaccine in a ready-to-use syringe format. Shingles is caused by reactivation of the varicella-zoster virus, the same virus responsible for chickenpox. Following an initial chickenpox infection, the virus can remain dormant in nerve tissue and reactivate later in life, particularly as immune function declines with age. Herpes zoster can cause a painful rash and may lead to postherpetic neuralgia, a persistent nerve-pain condition that can significantly affect quality of life. The availability of an additional vaccine presentation in Japan provides healthcare providers with another administration option while maintaining the established vaccine formulation and preventive purpose of Shingrix. The approval does not represent approval of a new vaccine molecule but rather expands the product’s authorized presentation.

Recombinant Vaccine Provides Shingles Protection

Shingrix is a recombinant, adjuvanted vaccine designed to stimulate an immune response against varicella-zoster virus. The vaccine contains a recombinant glycoprotein E antigen combined with GSK’s AS01B adjuvant system. The antigen helps the immune system recognize the virus, while the adjuvant is designed to enhance the resulting immune response. Unlike live attenuated shingles vaccines, Shingrix is a non-live vaccine, making its platform suitable for a broad range of adults for whom a non-live vaccination approach is preferred. Its use has expanded substantially in multiple markets as healthcare systems seek to reduce the burden of shingles and its complications. The vaccine has demonstrated strong efficacy against herpes zoster in clinical studies and is recommended for eligible adults in many countries according to local vaccination guidelines. The Japanese authorization of the prefilled syringe provides an additional product format for use within Japan’s vaccination system. The new presentation may also contribute to streamlined vaccine administration, potentially reducing preparation steps for healthcare professionals. However, the specific use, dosing schedule and eligible populations remain subject to Japanese regulatory requirements and local recommendations.

Approval Supports Broader Vaccine Access

The Japanese approval adds another milestone to the global development and commercialization of Shingrix, which has become an important component of GSK’s vaccines portfolio. Expanding product presentations can help pharmaceutical companies address different healthcare-system requirements and improve practical aspects of vaccine delivery. The development is particularly relevant for Japan because the country has a substantial aging population, and the risk of herpes zoster generally increases with age. Older adults are also at greater risk of complications following shingles, including prolonged nerve pain. Increasing convenient access to vaccination can therefore support broader preventive healthcare efforts. GSK continues to invest in vaccine research and development across infectious diseases, with a focus on addressing diseases that disproportionately affect older adults and other vulnerable populations. Shingrix remains a key example of a recombinant vaccine platform designed to provide durable protection against a disease associated with significant morbidity. The MHLW decision should be understood as a regulatory approval for the prefilled syringe presentation, rather than approval of Shingrix for an entirely new disease indication. The vaccine’s approved use and administration requirements in Japan remain governed by the country’s regulatory labeling and recommendations. For GSK, the authorization represents a further step in expanding the availability and usability of Shingrix in Japan. For healthcare providers and eligible adults, the prefilled syringe presentation offers another practical option for administering a vaccine designed to prevent herpes zoster and its potentially long-lasting complications. The approval also highlights the importance of not only developing effective vaccines but also improving their presentation and delivery to support real-world vaccination programs. As populations age and the burden of shingles remains significant, accessible vaccination strategies continue to play an important role in preventive healthcare.

Source: GSK press release